Royalty Pharma Plc(NASDAQ) RPRX

Royalty Pharma plc funds the development of new medicines. It buys rights to future sales of various therapies. These payments help researchers find new medical cures.

A Portfolio of Medical Rights

• Cystic Fibrosis Franchise: Rights to payments from therapies like Trikafta and Alyftrek; accounts for 33% of revenue for the six-month period ended June 30, 2026.
• Neurology and Rare Disease: Royalties from medicines such as Evrysdi for spinal muscular atrophy and Tysabri for multiple sclerosis.
• Oncology Treatments: Payments from cancer drugs including Xtandi for prostate cancer and Voranigo for brain tumors.
• Immunology and Respiratory: Interests in products like Tremfya for skin conditions and Trelegy for lung disease.

Recent Deals and Funding

• Acquired a royalty interest in Ziihera from Zymeworks for $250 million in Jan. 2026.
• Partnered with Johnson & Johnson in March 2026 to provide $500 million for autoimmune medicine development.
• Committed up to $500 million in Jan. 2026 to co-fund a Teva Pharmaceuticals program for vitiligo.
• Internalized management operations in May 2025 by acquiring its previously external manager.

What Makes the Business Work

The company uses a synthetic royalty model to provide cash to drug developers in exchange for future sales percentages. A synthetic royalty is a newly created right to a percentage of sales from a specific medicine. This passive approach avoids the high costs and risks of running clinical trials or manufacturing plants.

The Numbers Behind the Royalties

• Total income and other revenues reached $1.3 billion in the first six months of 2026, up 13.8% year over year.
• Portfolio Receipts grew to $1.7 billion for the six-month period ended June 30, 2026, up 8.4% year over year.
• Net income attributable to the company was $312.6 million in the first six months of 2026, up 15.1% year over year.
• Cash and cash equivalents totaled $812.0 million as of June 30, 2026.

Evolution of a Funding Pioneer

Royalty Pharma has moved from an external management structure to an internal one while growing its role as a primary financier for drug development. Its ability to generate cash from a diverse group of therapies allows it to fund new medical innovations continually.